Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), an ...

Clinical, histopathological, and molecular biomarkers in a multicentric cohort of Mexican women with triple-negative breast cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I ...

SCLC, researchers aimed to determine the consistency of benefit of adding PD-1/PD-L1 inhibitors to platinum-etoposide.

We read with interest the results of the HARMONi-6 trial by Zhiwei Chen and colleagues,1 which showed that ivonescimab plus chemotherapy improved progression-free survival versus tislelizumab plus ...

The field of cancer research has increasingly focused on the inflammatory response in colorectal and ovarian cancers due to its significant role in tumor progression. Colorectal cancer (CRC), the ...

Experts review a stage IV NSCLC case, debating whether to delay treatment while awaiting PD-L1 results to ensure a more ...

U.S. Food and Drug Administration (FDA) has approved a PD-L1 companion diagnostic test for patients with esophageal cancer or ...

Kazia Therapeutics Ltd. has announced promising preclinical and translational data supporting the development of NDL-2, a protein degrader targeting a newly identified mechanism of immunotherapy ...

AI may calculate PD-L1 scores for non-small cell lung cancer more accurately than manual assessment, results of an analysis ...

BioWorld - Monday, March 30, 2026 Breaking News: Trump administration impacts continue to roil the life sciences sector See today's BioWorld Science Home » Kazia Therapeutics reports data on nuclear ...